• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Rapport Therapeutics, Inc. - Common Stock (NQ:RAPP)

    29.02 -1.18 (-3.89%)
    Streaming Delayed Price Updated: 11:53 AM EST, Feb 26, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Rapport Therapeutics, Inc. - Common Stock

    < Previous 1 2 Next >
    News headline image
    Rapport Therapeutics to Participate in Upcoming Investor Conferences
    From Rapport Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Rapport Therapeutics Announces Accelerated Initiation of RAP-219 Phase 3 Program, Expansion of Epilepsy Portfolio, and Continued Progress Across the Pipeline
    From Rapport Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Rapport Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
    From Rapport Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Rapport Therapeutics Announces New Data and Post Hoc Analysis Demonstrating the Magnitude and Consistency of RAP-219’s Clinical Response in Patients with Focal Onset Seizures
    From Rapport Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Rapport Therapeutics to Present New Phase 2a Data Analysis Further Characterizing RAP-219 in Focal Onset Seizures at 2025 American Epilepsy Society Annual Meeting
    New analysis examines RAP-219’s effect during the first month of treatment and consistency of efficacy over the treatment period, effectiveness across baseline disease severities, and impact on seizure... 
    From Rapport Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Rapport Therapeutics Reports Third Quarter 2025 Financials and Provides Business Update
    From Rapport Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Rapport Therapeutics to Participate in Upcoming Investor Conferences
    From Rapport Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Rapport Therapeutics to Participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit
    From Rapport Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Rapport Announces Pricing of Public Offering of Common Stock
    From Rapport Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Rapport Announces Proposed Public Offering of Common Stock
    From Rapport Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Rapport Announces Positive Topline Results from Phase 2a Clinical Trial of RAP-219 in Patients with Focal Onset Seizures
    From Rapport Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Rapport Therapeutics to Announce Topline Results for RAP-219 Phase 2a Trial in Focal Onset Seizures on Monday, September 8, 2025
    From Rapport Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Rapport Therapeutics Reports Second Quarter 2025 Financials and Provides Business Update
    From Rapport Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Rapport Therapeutics Hosts Investor and Analyst Day; Provides Corporate Updates
    Phase 2a trial of RAP-219 in refractory focal epilepsy fully enrolled and on track for topline results in September 2025 
    From Rapport Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Rapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 46th Annual Global Healthcare Conference
    From Rapport Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Rapport Therapeutics to Host 2025 Investor and Analyst Day
    From Rapport Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Rapport Therapeutics Reports First Quarter 2025 Financials and Provides Business Update
    From Rapport Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Rapport Therapeutics to Participate in Upcoming Investor Conferences
    From Rapport Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Rapport Therapeutics to Present Data at the 2025 American Academy of Neurology Annual Meeting
    From Rapport Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Rapport Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
    From Rapport Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Rapport Therapeutics Announces Appointment of Dr. Jeffrey Sevigny as Chief Medical Officer to Drive Clinical Strategy and Precision Medicine Development
    From Rapport Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Rapport Therapeutics to Participate in Upcoming Investor Conferences
    From Rapport Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    CORRECTION -- Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS Disorders
    From Rapport Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS Disorders
    From Rapport Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Rapport Therapeutics Presents Data Demonstrating Consistent Association Between Decreases in RNS Measured Long Episodes and Meaningful Reductions in Clinical Seizures
    From Rapport Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Rapport Therapeutics to Present Data at American Epilepsy Society Annual Meeting
    Poster presentations on Phase 2a trial seizure biomarker, preclinical, and Phase 1 clinical data 
    From Rapport Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Rapport Therapeutics Reports Third Quarter Financials and Provides Business Update
    From Rapport Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Rapport Therapeutics to Present at Stifel Healthcare Conference and Jefferies London Healthcare Conference in November
    From Rapport Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Rapport Therapeutics to Present at Upcoming Epilepsy Medical Conferences
    From Rapport Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Rapport Therapeutics to Present at 22nd Annual Morgan Stanley Global Healthcare Conference and TD Cowen’s 4th Annual Novel Mechanisms in Neuropsychiatry Summit
    From Rapport Therapeutics, Inc.
    Via GlobeNewswire
    < Previous 1 2 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.